Our Q3 edition focuses on the evolution of outsourcing providers and innovations driving the future of healthcare. Experts from all facets of the industry discuss ongoing impacts from the COVID-19 pandemic, particularly to the supply chain, as well as topics spanning decentralized clinical trials, organ-on-a-chip technology, and increasing speed to the clinic.
Federal Equipment Company's Vice President Adam Covitt relates the unique approach that FEC took to the acquisition of an entire pharmaceutical manufacturing campus in Huntsville, Alabama.
Nigel Walker analyzes trends in OSD drug forms and the importance of CDMOs in supporting complex API projects.
Federal Equipment Company's Matt Hicks discusses the industry's efforts to simplify the supply chain, including reshoring U.S. manufacturing of APIs.
Arranta Bio CSO Aaron B. Cowley, Ph.D., explains how the company's extensive expertise in GMP tech transfer of LBPs can accelerate time to the clinic and the market.
Boyle Transportation's Andrew and Marc Boyle and CSafe Global's Patrick Schafer assess the challenges ahead in the global distribution of forthcoming COVID-19 vaccines.
New CEO Nick Green discusses his vision for Avid Bioservices' growth opportunities to take the company through the COVID-19 pandemic and beyond.
Grifols's Marga Viñes provides an overview of current trends impacting the market for parenteral drugs.
TriRx Chairman and CEO Tim Tyson reevaluates the responsibilities of different pharma stakeholders during pandemic times.
The same culture of innovation and flexibility that drives the company is proving invaluable in dealing with the challenges of the COVID-19 pandemic, says Paul Magreta of Grifols Recombinant Protein CDMO.
Biorasi's Mamta Trivedi examines the increasing importance of decentralized clinical trials models through the pandemic and beyond and discusses Biorasi's approach.
Northern Ireland is positioned to be an ideal location for second-source manufacturing of pharmaceuticals and medical devices, according to Kevin Holland, CEO of Invest Northern Ireland.
Alistair Davidson, Brittany Erana, and Rhonda Henry discuss PPD's commitment to decentralized clinical trial models and how they protect clinical research and patient safety.
Shiksha Mantri, Ph.D., and Adela Kasselkus, Ph.D., of Millipore Sigma highlight the importance of high-quality reagents and production methods for lipid-based delivery systems.
Gustavo Mahler, Ph.D. and Jessica Davis of Dynamk Capital discuss the underlying innovations and extensive potential for application of organ-on-a-chip technologies.
The evolving cell and gene therapy modalities require similar innovation and transformation of bioanalytical methods, says Celerion's Timothy Sangster.
AKDYS co-founders Stephan Kutzer, Ph.D., and Danielle Young discuss the importance of data- and science-driven decision-making across pharma operations.
Peter Soelkner, Managing Director of Vetter Pharma International GmbH, and Frank Mathias, Ph.D., CEO of Rentschler Biopharma SE explain how the two companies' new collaborative partnership provides new synergies to support customer projects throughout the life cycle.
Thomas Lynch, Ph.D. discusses the potential of CRISPR RNPs for cell and gene therapy and Aldevron's manufacturing capabilities.
The Pharma's Almanac editorial team discusses how the COVID-19 pandemic has aggravated existing issues with the pharmaceutical supply chain.
The Pharma's Almanac editorial team discusses how the COVID-19 pandemic has aggravated existing issues with the pharmaceutical supply chain.
Our editors explore the increased demand for local manufacuturing and outsourcing partners during the pandemic.
We attempt to anticipate the long-term changes to the pharma/biopharma supply chain following the resolution of the COVID-19 pandemic.
The Nice Insight team explains the creative thinking behind That's Nice's rebranding of Yourway to support its reconfiguration into a full-service premium biopharma courier and clinical trials logistics organization.
Nice Insight highlights the creative work underlying the development of the Arranta Bio brand.
Sosna + Co.'s Erica and Adam Sosnowski highlight the impact of the COVID-19 pandemic on natural health and cannabis products.
SPI Pharma continues to prioritize the qualification and validation of alternative sources –– a strategic objective invaluable to enable them to face a supply chain risk from China that grew into a global pandemic.
How Is Dynamk Facing the Future of Healthcare?
Being able to provide end-to-end clinical trials solutions and services enables SanaClis to become more of a partner, ensuring that a study reaches its next phase or market authorization.
Polpharma Biologics has always sought to function as a partner in drug development, so they not only offer fully integrated discovery to commercial supply services but clinical, regulatory, and IP support.
TriRx is building additional capabilities to service the full supply chain, including the acquisition of materials, a broader capability of dosage forms, and additional supply chain services.
New equipment technologies will need to be developed to keep manufacturing costs manageable for existing and future products., but for now, the industry will need to rely on existing manufacturing equipment and facilities.
SGD Pharma maintains its focus on customers by taking a Global Account Management approach and aligning different models and processes with their relevant needs.
Globyz Biopharma Services is investing in facilities and temperature-controlled capabilities to become a leading one-stop shop for global comparator sourcing.
Going forward, manufacturing companies should be able to reliably produce small batches of highly complex, potent drug formulations for smaller but better-understood patient populations.
Avara is currently focused on their existing network and core capabilities of oral solid dose and sterile manufacturing services across the Americas and Europe.
Arranta Bio has more than 10 years of experience in manufacturing challenging LBPs, including species that clients may be skeptical about being able to produce.
The Yourway team is aligned in their commitment to better the lives of patients and embrace every project with the utmost dedication regardless of its size or scope.
In the first part of a series, Haig Armaghanian explores the challenges the COVID-19 pandemic has brought to the pharmaceutical supply chain and the issues surrounding attempts to reshore U.S. manufacturing.
Altis Biosystems co-founder Nancy Allbritton discusses how microphysiological systems, like Altis's RepliGut, enable more efficient and cost-effective drug discovery and development.
Nice Consulting's Guy Tiene relates some of the insights gained through his experience assisting pharma companies in mergers and acquisitions.
Nice Insight's Nigel Walker discusses the inherent challenges in conducting M&A activity during a pandemic
Patrick Hatem relates Avara's experience with successful conversions of drugs from prescription to over the counter forms at their Aiken facility.
Nice Insight's Research Director TJ Ladage provides an overview of efforts to repurpose existing, approved drugs to combat COVID-19.
Founder and CEO Pascal Descargues, Ph.D., explains how Genoskin's living human skin models provide better translation of preclinical findings than animal models.
Medevice Capital President Cécile Real discusses the how Medevice works as both an investment firm and a business development partner to its portfolio companies.
Ann McMahon and Pamela Barton relate how an integrated supplier like Catalent can help clients get biologics to the clinic faster and more efficiently.
The endocannabinoid system is a ripe source of drug targets for a range of indications, according to Artelo Biosciences, Inc. President, CEO, and Director Gregory Gorgas.
Sylvain Marcel, Ph.D., Robert Erwin, and Brian R. Berquist, Ph.D., discuss how iBio's FastPharming plant-based production system, along with its VLP and LicKM platforms, are well suited to the accelerated development of vaccines.
David Holliday, DMS, and Mark Krause of Evolve Biologics discuss an alternative plasma protein production technology that promises to further unlock the therapeutic potential of plasma proteins.
Mark Sawicki and Robert Jones of Cryoport walk us through recently updated ISO guidelines seeking to standardize best practices for the storage and transportation of cell and gene therapies.
Theresa Heah, M.D. describes how AsclepiX Therapeutics' takes a unique approach to computational biology and rational drug design to uncover candidate treatments to restore homeostasis in ocular diseases and oncology.
President, CEO, and Director Glenn Mattes discusses TFF Pharmaceuticals unique thin-film freezing (TFF) technology and how it addresses both solubility and storage and handling issues for parenteral drugs.
A panel of SMEs discusses how the industry is restructuring supply chains in response to the COVID-19 pandemic.
Industry experts discuss possible steps to address drug pricing issues.
.svg)
